obtained, but a more complete mechanistic explanation will require further investigation ( 4 ) .
The authors note that the imatinib-resistant patients in this cohort responded to dasatinib ( Figure 1, C ) , an established inhibitor of BCR-ABL and LYN kinases, as well as all other SRC family members. Although both the siRNA and inhibitor studies are consistent with LYN kinase involvement, one potentially informative experiment to further gauge the extent of dependence on LYN signaling would be to examine whether ex vivo treatment with the ABL and LYN dual tyrosine kinase inhibitor INNO-406 reproduces the cellular and biochemical responses observed after dasatinib treatment. Testing with nilotinib, which does not block kinase activity of the SRC family but can be effective in imatinib-resistant CML, would address whether more complete inhibition of BCR-ABL kinase activity relative to imatinib can shut down the putative BCR-ABL -independent LYN axis. Additionally, although the authors fi nd no evidence of activating point mutations in LYN in imatinib-resistant patients, it would be interesting to see whether expression of a "gatekeeper-mutated" variant of LYN (the equivalent of T315I in ABL ) in imatinib-resistant cells that overexpress LYN kinase would render these cells dasatinib resistant. Clearly, detecting such a mutation in a patient who does not respond to dasatinib treatment and also lacks a BCR-ABL mutation would be the ideal "experiment of nature" to support the importance of LYN for resistance.
An intriguing question arising from this work centers on the mechanism of activation of LYN kinase in the absence of upstream BCR-ABL signaling. One possibility is that cells from at least some patients with imatinib-resistant, BCR-ABL mutation-negative CML have instigated a "rewiring" of the LYN signaling cascade to establish or increase the reliance on an auxiliary BCR-ABLindependent mechanism ( Figure 1, B ) . Of note, overexpression of LYN kinase in imatinib-sensitive CML cells resulted in moderately reduced imatinib sensitivity resembling the level observed for weakly imatinib-resistant BCR-ABL mutations that can be overridden by dose escalation. This observation may imply that most or all of the components necessary for BCR-ABL -independent LYN activation are present but that events leading to rewiring
have not yet occurred. Introduction of a constitutively activated LYN construct into imatinib-sensitive cells could potentially shed light on this issue. If phosphorylation of LYN is a crucial step toward BCR-ABL -independent disease, these cells might be expected to exhibit more profound resistance to imatinib. It would also be of interest to carry out LYN coimmunoprecipitation experiments with lysates from these cells to see if increased association with c-Cbl and/or the 80-kDa protein is observed. Also, it should be noted that, although an accurate estimate of incidence will require surveying a much larger patient population, persistent LYN signaling probably does not account for all patients with mutation-negative BCR-ABL who fail to respond to treatment (eg, dasatinib nonresponders).
We know that BCR-ABL participates in the activation of SRC family kinases, although likely not although direct phosphorylation. Although studies ( 5 ) in mice that are null for the three SRC kinases that are principally expressed in the myeloid lineage (LYN, HCK, and FGR) have revealed that BCR-ABL does not require SRC kinases to induce a myeloproliferative disease, this result does not preclude the possibility that a SRC kinase could replace BCR-ABL kinase in a cell that has managed to rewire. In this scenario, however, what is driving LYN activation? Although the authors detected no mutations in LYN , they found an abnormal phosphorylation pattern, implicating an as yet unidentifi ed tyrosine kinase upstream of LYN or an abnormal adaptor protein that facilitates abnormal substrate utilization. We can only speculate whether this putative mechanism of transferred addiction in the face of sustained inhibition of BCR-ABL is driven by somatic mutations or is the result of plasticity that allows some cells to adapt to a situation in which BCR-ABL kinase is inhibited. Dissecting the underlying mechanism will be challenging. The work of Wu et al. in this issue ( 3 ) takes us outside of the realm of thoroughly studied kinase domain mutation-based resistance and toward an improved understanding of BCR-ABL -independent disease. In addition to opening new questions for exploration, these results suggest that therapies targeting both BCR-ABL and LYN kinases may prove benefi cial in certain circumstances of imatinib-resistant CML.
